

VISION

The Department of Otorhinolaryngology shall be an internationally recognized center of excellence in the field of Otorhinolaryngology and Head and Neck Surgery

MISSION

The health needs of the Filipino shall be its prime consideration.

It shall provide excellence and leadership in the different aspects in Otolaryngology – Head and Neck Surgery by teaching, providing exemplary clinical practice and dynamically pursuing relevant researches beneficial to the community in an environment guided by moral, ethical and spiritual values.



General Information

- F.F.
- 40/F
- Single
- Roman Catholic
- Lives in Quezon City

18 years prior to admission

2000

- 2x2 cm soft, irregularly shaped, movable nontender anterior neck mass
 - (-) dysphagia, (-) dyspnea, (-) hoarseness, (-) palpitations, (-) weight changes, (-) tremors, (-) heat/cold intolerance, (-) easy fatigability
- No consult done or meds taken

In the interim

- No increase in size of the anterior neck mass
- No appearance of other masses
- No onset of new symptoms

10 years prior to admission

- Slight increase in the size of the anterior neck mass, no symptoms
- Unable to consult due to lack of resources

8 years prior to admission

- Consulted with a private physician where no work-up was done
- Assessment: hyperthyroidism
- Plan: methimazole 5mg/tab, 1 tab daily for 3 months with follow-up
- Complied with medication for one month and did not follow up




In the interim

- Gradual increase in the size of the mass but no change in consistency, or pain
- No palpable lymph nodes
- (-) dysphagia, (-) hoarseness, (-) dyspnea, (-) palpitations, (-) easy fatigability, (-) weight changes
- No repeat consult done



3 years prior to admission

- Further increase in size of the initial neck mass extending to involve the left side of the neck
- No associated symptoms
- No consult or intake of medication



1 year prior to admission

- Increase in mass size, extending to involve the right side of the neck
- Consult with a private physician where FT4 and TSH levels were taken and assessed to be normal
- Advised neck ultrasound and, subsequently, surgery

Neck ultrasound (2/13/2017):

- Bilaterally enlarged multinodular thyroid gland
 - Multiple well-defined solid foci, right lobe
 - Solid masses, left lobe



4 months PTA

- Opted to seek a second opinion at PGH and was seen at the ORL OPD where FNAB and FT4 TSH were ordered
 - A> multinodular nontoxic goiter
- Advised admission and surgery

Fine needle aspiration biopsy (10/19/2017):

Bethesda Category II
Cell findings consistent with
colloid nodule

FT4 = 10.89TSH = 0.8508

2000 **2008** 2010 2017

Review of Systems

- (-) fever
- (-) headache
- (-) dizziness
- (-) blurring of vision
- (-) epistaxis

- (-) nasal congestion
- (-) chest pain
- (-) cough
- (-) abdominal pain
- (-) diarrhea/constipation

- (-) dysuria
- (-) polyuria
- (-) nocturia
- (-) numbness
- (-) edema

Past Medical History

- (-) hypertension
- (-) diabetes
- (-) bronchial asthma
- (-) tuberculosis
- (-) heart disease
- (-) cancer
- (-) liver disease
- (-) kidney disease
- (-) previous surgeries
- (-) allergies

Family Medical History


- (+) thyroid disease (sister, paternal grandmother)
- (+) diabetes (father)
- (-) hypertension
- (-) heart disease
- (-) cerebrovascular disease
- (-) bronchial asthma
- (-) tuberculosis
- (-) cancer

Personal and Social History

- Occasional smoker (2 sticks/week)
- Non alcoholic beverage drinker
- Denies illicit drug use
- High school graduate
- Stay at home mom
- 2 sexual partners and cohabits with the current partner

Obstetric History

- Menarche: 12 years old
- Interval: 2-3 months
- Duration: 7 days
- Amount: 3 pads per day
- (-) dysmenorrhea
- G4P4 (4004)
 - Spontaneous vaginal delivery
 - Eldest born in a hospital, three born at home assisted by a midwife
 - No fetomaternal complications



SYSTEMIC PE

- VITAL SIGNS: BP 110/80, HR 66, RR 18, Temp 36.7, Ht 150cm, Wt 72.9 kg
- GENERAL: awake, coherent, ambulatory, not in cardiorespiratory distress
- CARDIAC: adynamic precordium, normal rate with regular rhythm, no murmurs
- PULMONARY: equal chest expansion, clear breath sounds, no rhonchi/wheezes/crackles

- ABDOMEN: soft abdomen, normoactive bowel sounds, no tenderness
- **EXTREMITIES:** full and equal pulses, pink nail beds, good capillary refill time, no edema
- **SKIN**: no lesions

HEAD & NECK EXAMINATION



(+) 7 x 4.5 x 2 cm firm, round, nontender, movable mass at the upper pole of the left lobe of the thyroid
 (+) 10 x 7 x 2 cm firm, irregularly shaped, nontender, movable mass at the mid to lower pole of the left lobe of the thyroid extending into the isthmus

(+) 4 x 3 x 1 cm soft, irregularly shaped, ill-defined, nontender, movable mass at the middle segment of the right lobe of the thyroid

All masses move with deglutition; no cervical lymphadenopathies

HEAD & NECK EXAMINATION



- (+) 7 x 4.5 x 2 cm firm, round, nontender, movable mass at the upper pole of the left lobe of the thyroid
 (+) 10 x 7 x 2 cm firm, irregularly shaped, nontender, movable mass at the mid to lower pole of the left lobe of the thyroid extending into the isthmus
 - (+) 4 x 3 x 1 cm soft, irregularly shaped, ill-defined, nontender movable mass at the middle segment of the right lobe of the thyroid

All masses move with deglutition; no cervical lymphadenopathies

OTOLOGIC EXAM






AU: (+) patent EAC, (+) intact TM, (+) cone of light, (-) erythema, (-) discharge, (-) masses

ORAL CAVITY EXAM



Pink oral mucosa
Tongue and uvula midline
Two missing molars
(-) dental caries, masses, lesions

RHINOSCOPIC EXAM



Midline septum, (-) intranasal masses, discharge

INDIRECT LARYNGOSCOPY



Fully mobile vocal cords



Pertinent Diagnostics

- ULTRASOUND GUIDED FNAB (Oct, 2017)
 - Bethesda Category II: consistent with colloid nodule
- FT4 (1/24/2018): 11.57
- TSH (1/24/2018): 0.7331
- NECK ULTRASOUND (Feb. 2, 2017)
 - The right thyroid lobe measures 8.54 x 3.33 x 2.37 cm
 - Multiple well-defined solid foci are seen measuring as follows:
 - Upper pole 1.25 x 1.08 x 0.95cm, 0.88 x 0.83 x 0.69 cm, and 0.78 x 0.73 x 0.57 cm
 - Midsegment 0.54 x 0.58 x 0.50 cm and 3.90 x 2.95 x 2.24 cm
 - Lower pole 1.90 x 1.82 x 1.14 cm and 0.94 x 1.04 x 0.58 cm
 - These foci exhibit peripheral vascular flow

Pertinent Diagnostics

- NECK ULTRASOUND (Feb. 2, 2017)
 - The left thyroid lobe measures 13.69 x 8.70 x 5.05 cm
 - Solid masses are noted:
 - Upper pole 5.99 x 5.86 x 4.03 cm
 - Mid segment 6.93 x 6.49 x 3.98 cm
 - Lower pole 6.27 x 6.30 x 4.73 cm
 - No significant intralesional vascular flow noted within these masses
 - The isthmus is thickened and measures 0.63 cm
 - Impression: bilaterally enlarged multinodular thyroid gland


Salient points

- This is a case of multinodular nontoxic goiter in a 40/F with an 18 year history of a gradually enlarging thyroid mass and a family history of benign thyroid disease.
- Neck ultrasound revealed multiple solid masses in both thyroid lobes, predominantly on the left with a FNAB Bethesda category II.



Thyroid Anatomy

- Two lobes, joined by the isthmus
 - 4 x 1.5 x 2 cm, 15-25 g
 - Pyramidal lobe
- Connected to the cricoid cartilage via the posterior suspensory ligament
- Supplied by the superior and inferior thyroid arteries



Flint, P., Haughey, B., Robbins, K., Thomas, J., Niparko, J., Lund, V. and Lesperance, M. (2014). Cummings Otolaryngology - Head and Neck Surgery. London: Elsevier Health Sciences.

Multinodular Nontoxic Goiter

Epidemiology

National Nutrition Surveys

• 1987: 3.7%

1993: 6.7%

PhilTiDeS

- 8.9% had goiters
 - 56% diffuse goiter
 - 44% nodular goiter
- 9.11% of those who had normal TFTs had goiters


Table 4. Distribution of the sample population according to biochemical status and presence or absence of goiter


Functional status	Total	No goiter	With goiter
Normal	4446	4025 (90.89%)	421 (9.11%)
True Hyperthyroidism	30	14 (47.18%)	16 (52.82%)
Subclinical hyperthyroidism	255	216 (85.39%)	39 (14.61%)
True Hypothyroidism	19	16 (84.32%)	3 (15.68%)
Subclinical hypothyroidism	109	96 (89.30%)	13 (10.7%)
Total	4859	4367 (89.87%)	492 (10.13%)

Carlos-Raboca, J., Jimeno, C., Kho, S., Andag-Silva, A., Jasul, Jr., G., Nicodemus, Jr., N., Cunanan, E., & Duante, C. (2014). The Philippine Thyroid Diseases Study (PhilTiDeS 1): Prevalence of Thyroid Disorders Among Adults in the Philippines. *Journal of the ASEAN Federation of Endocrine Societies*, 27(1), 27. Retrieved from http://asean-endocrinejournal.org/index.php/JAFES/article/view/9/400

Etiology

- 1. Hyperplasia
- 2. Altered growth and function
- 3. Increased growth factors





Primary Factors

- •Functional heterogeneity of normal follicular cells, due to genetic and acquisition of new inheritable qualities by replicating epithelial cells
- Gender (women)
- Subsequent functional and structural abnormalities in growing goiters
- •Elevated TSH (induced by iodine deficiency, natural goitrogens, inborn errors of thyroid hormone synthesis)
- Smoking, stress, certain drugs
- Other thyroid-stimulating factors (IGF-1 and others)
- Endogenous factor (gender)

Secondary Factors

Medeiros-Neto, G. (2016). Multinodular goiter. Retrieved from http://www.thyroidmanager.org/chapter/multinodular-goiter/

Course of the Disease

- Minimal diffuse enlargement noted at adolescence or puberty
- Sudden growth spurt in longstanding anterior neck masses
- Initial consult
 - Presence of the neck mass
 - Found on routine examination by physician
 - Pressure symptoms




Clinical Symptoms in the Diagnosis of MNG


- Often family history of benign thyroid disease
- Slowly growing anterior neck mass
- Uni- or multinodularity on examination
- Enlargement during pregnancy
- Cosmetic complaints
- Asymmetry, tracheal deviation, and/or compression
- Rarelly upper airway obstruction, dyspnea, cough, and dysphagia
- Sudden transient pain or enlargement secondary to hemorrhage
- Gradually developing hyperthyroidism
- Superior vena cava obstruction syndrome (rare)
- Recurrent nerve palsy (rare)
- Horner's syndrome (rare)

ASSESSMENT


Multinodular non-toxic goiter








High Suspicion >70-90%











Intermediate Suspicion 10-20%







Low Suspicion 5-10%













Very low Suspicion <3%









FF Thyroid ultrasound findings

R thyroid lobe

- Measures 8.54x3.33x2.37cm
- Multiple well-defined solid foci are seen, measuring as follows:
 - Upper pole: 1.25x0.95cm, 0.88x0.83x0.69cm, 0.78x0.73x0.57cm
 - Mid segment: 0.54x0.58x0.5cm, 3.9x2.95x2.24cm
 - Lower pole: 1.9x1.82x1.14cm, 0.94x1.04x0.56cm

FF Thyroid ultrasound findings


L Thyroid lobe

- Measures 13.69x8.7x5.05cm
- Solid masses noted:
 - Upper pole: 5.99x5.86x4.03cm
 - Mid segment: 6.93x6.49x3.98cm
 - Lower pole: 6.27x6.3x4.73cm
- No significant intralesional vascular flow noted within these masses

Isthmus measures 0.63cm and is thickened

FF Thyroid ultrasound findings

Results are suggestive of Low suspicion pattern



Bethesda System for reporting Thyroid Cytopathology

Diagnostic category	Risk of malignancy if NIFTP ≠ CA (%)	Risk of malignancy if NIFTP=CA (%)	Usual management ^a
Nondiagnostic or unsatisfactory	5-10	5–10	Repeat FNA with ultrasound guidance
Benign	0-3	0–3	Clinical and sonographic follow-up
Atypia of undetermined significance or follicular lesion of undetermined significance	6–18	~10–30	Repeat FNA, molecular testing, or lobectomy
Follicular neoplasm or suspicious for a follicular neoplasm	10–40	25–40	Molecular testing, lobectomy
Suspicious for malignancy	45-60	50-75	Near-total thyroidectomy or lobectomy ^{b,c}
Malignant	94–96	97–99	Near-total thyroidectomy or lobectomy ^c

I: Nondiagnostic or unsatisfactory

- Inadequate samples
- Includes those with obscuring blood, poor cel'l preservation, insufficient sample of follicular cells
- Only cyst contents

- Recommendation: Repeat FNA with ultrasound guidance
 - If persistent, excision is considered

II: Benign

- Abundant colloid usually
- Very low false-negative rate
- Recommendation: Clinical and sonographic follow-up

III: Atypia of undetermined significance

- Detection of risk of malignancy is challenging
- Subclassification of atypia:
 - **≻**Cytologic
 - > Architectural
 - ➤ Cytologic and architechtural
 - >Hurthle cell
 - ➤ Atypia, not otherwise specified
- A category of last resort
- Recommendation: Repeat FNA, molecular testing or lobectomy

IV: Follicular neoplasm or suspicious for a follicular neoplasm

- Most are hyperplastic proliferations of follicular cells, commonly of multinodular goiter
- "Follicular-patterned cases with mild nuclear changes", but without true papillae and intranuclear pseudoinclusions
- Recommendation: Molecular testing, lobectomy

V: Suspicious for malignancy

- Raise the possibility of Follicular variant Papillary Thyroid CA or Noninvasive follicular thyroid neoplasm with papillary-like nuclear features
- Guides clinical team towards direction of lobectomy if lesion is confined to just one side
- Recommendation: Near-total thyroidectomy or lobectomy

VI: Malignant

- Conclusive
- Descriptive comments that follow are used for subclassification
- Limited to those with "classical" features of malignancy
- Recommendation: Near-total thyroidectomy or lobectomy

FF – FNAB results

- Cat II: Benign
- Consistent with colloid nodule with cystic degeneration



Total Thyroidectomy



Five-year Follow-up of a Randomized Clinical Trial of Total Thyroidectomy versus Dunhill Operation versus Bilateral Subtotal Thyroidectomy for Multinodular Nontoxic Goiter

Marcin Barczyński · Aleksander Konturek · Alicja Hubalewska-Dydejczyk · Filip Gołkowski · Stanisław Cichoń · Wojciech Nowak



Background

- Extent of thyroid resection in bilateral multinodular nontoxic goiter (MNG) remains controversial in other countries
- Low-volume surgeons avoid performing total thyroidectomy due to possible complications
 - Permanent recurrent laryngeal nerve (RLN) palsy
 - Permanent hypothyroidism
- However, there is increasing acceptance for total thyroidectomy in bilateral MNG
 - Eradicates disease process
 - Lowers recurrence rate
 - Avoid substantial risk for surgery
 - Minimal risk of morbidity

Background

 To evaluate results of various resection modes (Total Thyroidectomy, Dunhill Procedure, Bilateral Subtotal Thyroidectomy) with special emphasis on the recurrence rate and morbidity rate in a 5 year follow up




Fig. 1
Flow diagram of the study showing the number of patients randomized originally and available for follow-up at 5 years



Surgical Technique

- All operation were performed by 3 same experienced endocrine surgeons
 - ~ 1/3 of the operation in each study groups was done by each surgeon
- Total Thyroidectomy
 - Extracapsular Thyroidectomy
- Dunhill Operation
 - Unilateral extracapsular total thyroidectomy and contralateral subtotal thyroid lobe resection (~2g normal thyroid tissue)
- Bilateral Subtotal Thyroidectomy
 - Bilateral subtotal thyroidectomy (~2g of normal thyroid tissue, bilateral)

Preoperative Evaluation

- High resolution doppler ultrasound of the neck was done by a single endocrine surgeon experienced in thyroid imaging
- FNA was performed in all patients prior to the study
- Serum FT3, FT4, TSH and TPO

Postoperative Follow-up

- Ultrasonographic, cytologic and biochemical follow-up 60 months postop
- Indirect laryngoscopy
- Serum calcium

Table 1
Demographic characteristics of 570 patients who completed the 5-year follow-up

	TT (n = 191)	DO (n = 189)	BST (n = 190)
Sex ratio (M:F) ^a	17:174	20:169	16:174
Mean age, years ^b	46.51 ± 14.11	47.22 ± 15.61	48.23 ± 15.44
Preoperative TSH, mIU/l ^b	1.90 ± 0.89	1.82 ± 0.81	1.78 ± 0.92
Preoperative thyroid volume (assessed by ultrasound), ml	76.6 ± 38.9	77.8 ± 39.5	78.9 ± 40.1

TT total thyroidectomy; DO Dunhill operation; BST bilateral subtotal thyroidectomy; TSH thyroid stimulating hormone

^aχ2-test

^bt-test; statistically nonsignificant differences for all values

Table 3

Final pathology and need for completion thyroidectomy for 570 patients who completed the 5-year follow-up

	TT (n = 191)	DO (n = 189)	BST (n = 190)		
Benign multinodular goiter, n (%)	173 (90.58)	174 (92.06)	174 (91.58)		
Incidental thyroid cancer, n (%) ^a					
Total	18 (9.42)	15 (7.94)	16 (8.42)		
Papillary	15 (7.85)	13 (6.88)	13 (6.88)		
pTiaNoMo	12 (6.28)	11 (5.82)	11 (5.82)		
pTimNoMo	3 (1.57)	2 (1.05)	2 (1.05)		
Follicular, pT2NoMo	2 (1.05)	1 (0.53) ^b	2 (1.05)		
Hürthle cell, pT2NoMo	1 (0.53)	1 (0.53)	1 (0.53)		
Need for completion thyroidectomy, n (%)					
Total	1 (0.52) [†]	3 (1.57)	7 (3.68) [†]		
For cancer	o (o) [‡]	2 (1.05)	5 (2.63)‡		
For goiter recurrence	1 (0.53)	1 (0.53)	2 (1.05)		

Differences were statistically nonsignificant, unless otherwise indicated (χ^2 -test: † p = 0.03; † p = 0.01)

Table 2

Recurrence rate, timing of nodular goiter recurrence, and levothyroxine substitution data among 570 patients who completed the 5-year follow-up

Follow-up time, months	Goiter recurrence, n (%)			
	TT (n = 191)	DO (n = 189)	BST (n = 190)	
0-12	o (o)	0 (0)	o (o)	
24	o (o)	1 (0.52)	2 (1.05)	
36	1 (0.52)	2 (1.05)	3 (1.57)	
48	o (o)	3 (1.57)	7 (3.68)	
60	o (o)	3 (1.57)	10 (5.26)	
Total recurrence	1 (0.52) ^{†‡}	9 (4.71) [†] *	22 (11.58) [‡] *	
Mean levothyroxine dose, μg ^a	100.59 ± 14.53** [#]	96.29 ± 17.78** [§]	77.16 ± 24.30 ^{#§}	

 χ^2 test: $^{\dagger}p = 0.01$; $^{\ddagger}p < 0.001$; $^{*}p = 0.02$; $^{**}p = 0.04$; $^{\sharp\S}p < 0.001$

^aMean cumulated levothyroxine substitutive dose during 5-year follow-up

^aStaging according to International Union against Cancer (UICC) TNM classification (2002)

^bA case of minimally invasive follicular thyroid cancer




Fig. 3 Five-year follow-up data of mean volume of the remnant thyroid tissue (assessed by ultrasonography at yearly intervals). The remnant thyroid volume in the BST group was significantly larger after 60 months of follow-up (paired t-test: p < 0.001), whereas nonsignificant differences were observed in the DO group




Fig. 4 Five-year follow-up data of mean volume of the remnant thyroid tissue in the BST group (assessed by ultrasonography at yearly intervals). The remnant thyroid volume in 22 patients with recurrence versus 168 patients without recurrence was significantly larger from 24 to 60 months of follow-up (paired t-test; p < 0.001)

Table 4
Operative time and complications after thyroidectomy among 570 patients who completed the 5-year follow-up

	TT (n = 191)	DO (n = 189)	BST (n = 190)		
Operating time, min	69.12 ± 14.23	68.31 ± 14.18	67.12 ± 13.94		
Hypoparathyroidism, n (%)					
Total	22 (11.52)†‡	8 (4.23)‡	4 (2.10)†		
Transient	21 (10.99)†‡	8 (4.23)‡	4 (2.10)†		
Permanent	1 (0.53)	0 (0)	0 (0)		
Recurrent laryngeal nerve injury, n (%) ^a					
Total	25 (6,54)*	19 (5.02)	10 (2.63)*		
Temporary	21 (5.49)§	16 (4.23)	8 (2.10)§		
Permanent	4 (1.05)	3 (0.79)	2 (0.53)		
Hemorrhage, n (%)	0 (0)	1 (0.53)	2 (1.05)		

Conclusion

 Total Thyroidectomy can be regarded as the procedure of choice in patients with Multinodular Goiter with significant lower incidence of goiter recurrence and less frequent need for completion thyroidectomy.

• This however confers a significantly higher risk of postoperative transient but not permanent hypoparathyroidism and recurrent laryngeal nerve paresis.




Introduction

- A significant proportion of the population have thyroid nodules (20-76%)
- Majority are benign (Cat II)
- ATA 2015 guidelines for benign thyroid nodules
 - TSH suppression NO LONGER RECOMMENDED (strong recommendation, high quality evidence)
 - Surgery (weak recommendation, low-quality evidence)
 - If nodules are large (>4 cm)
 - Compressive symptoms
 - Clinical suspicion of malignancy
 - Observation (strong recommendation, low-quality evidence)
 - Percutaneous ethanol injection for cystic nodules (weak recommendation, low-quality evidence)

Percutaneous treatments

- Image-guided ablation of thyroid nodules
- Ethanol
 - Disadvantages: hoarseness (ethanol leakage)
- Laser ablation
 - Disadvantages: transient hyperthyroidism, hematoma, hoarseness
- Radiofrequency
 - Applies thermal energy to induce tissue necrosis of thyroid nodules
 - Disadvantages: may induce autoimmune thyroid disease, skin burns, adhesion formation





Medicine (Baltimore). 2016 Aug; 95(34): e4659.

Published online 2016 Aug 26. doi: <u>10.1097/MD.000000000004659</u>

Radiofrequency ablation for treatment of benign thyroid nodules

A PRISMA-compliant systematic review and meta-analysis of outcomes

Fen Chen, PhD,^a Guo Tian, MD,^b Dexing Kong, PhD,^c Liyun Zhong, MD,^d and Tian'an Jiang, PhD^d,*

Monitoring Editor: Eleonore Fröhlich.



Methodology

- Meta-analysis of all published literature until January 27, 2016
- Inclusion criteria
 - Original reseach
 - Retrospective or prospective studies
 - Examined any or all of the following results
 - Nodule volume
 - Largest diameter
 - Symptom score
 - Cosmetic score
 - TSH, fT3. fT4
 - vascularity

- 20 studies
- 1090 patients

• Age: 13-89 years old

• Sex: 78.6% female

Table 3Subgroup analysis of the outcomes before and after RFA.

Subgroup	Number of studies	SMD (95%CI)	Z score	P^*
Nodule volume				
1 mo	9	0.83 (0.47-1.19)	4.54	< 0.001
3 mo	7	1.31 (0.76-1.85)	4.67	< 0.001
6 mo	15	1.25 (0.90-1.59)	7.03	< 0.001
12 mo	6	4.16 (2.25-6.07)	4.27	< 0.001
Last month	20	1.73 (1.27-2.18)	7.43	< 0.001
Cold nodule	10	2.02 (1.10-2.93)	4.32	< 0.001
Hot nodule	5	2.05 (0.88-3.21)	3.44	0.001
Largest diameter	7	1.43 (0.97-1.90)	6.06	< 0.001
Symptom score	16	3.11 (2.28-3.94)	7.32	< 0.001
Cosmetic score	12	2.77 (2.18-3.36)	9.17	< 0.001
TSH	8	-0.44 (-0.86 - 0.02)	2.03	0.042
T3	4	0.33 (0.06-0.60)	2.43	0.015
fT4	7	0.46 (-0.29-1.22)	1.20	0.230
Vascularity	2	1.78 (0.31-3.25)	2.38	0.017

Discussion

- RF ablation also affects thyroid vascularity which leads to reduced production of T3 and T4 and accelerated secretion of TSH
- Symptoms and cosmesis also improved

Limitations

- Heterogenous inclusion criteria
- Limited sample size
- Selection bias most studies came from Korea, Italy

